Table 1.
| Variable | Total cohort (N=7,880,950 [100%]) | Boosted individuals (n=3,940,475 [50.0%]) | Unboosted controls (n=3,940,475 [50.0%]) | Standardized difference |
|---|---|---|---|---|
| Follow-up (d) Median (p25-p75) [min-max] |
49 (29-67) [10-141] | 49 (29-67) [10-141] | 49 (29-66) [10-141] | 0.0091 |
| Age (y), median (p25-p75) | 74 (70-80) | 74 (70-80) | 74 (70-80) | −0.0235 |
| COVID-19 original vaccine | 0 | |||
| Pfizer | 4,035,158 (51.2) | 2,017,579 (50.0) | 2,017,579 (50.0) | |
| Moderna | 3,845,792 (48.8) | 1,922,896 (50.0) | 1,922,896 (50.0) | |
| Age group (y) | 0 | |||
| 66-70 | 2,248,536 (28.5) | 1,142,336 (50.8) | 1,106,200 (49.2) | |
| 71-75 | 2,169,531 (27.5) | 1,087,005 (50.1) | 1,082,526 (49.9) | |
| 76-80 | 1,526,810 (19.4) | 757,068 (49.6) | 769,742 (50.4) | |
| 81-85 | 1,006,481 (12.8) | 496,829 (49.4) | 509,652 (50.6) | |
| ≥86 | 929,592 (11.8) | 457,237 (49.2) | 472,355 (50.8) | |
| Sex | 0 | |||
| Male | 3,285,584 (41.7) | 1,642,792 (50.0) | 1,642,792 (50.0) | |
| Female | 4,595,366 (58.3) | 2,297,683 (50.0) | 2,297,683 (50.0) | |
| Race | 0 | |||
| Non-Hispanic White | 6,807,760 (86.4) | 3,403,880 (50.0) | 3,403,880 (50.0) | |
| Non-Hispanic Black | 337,824 (4.3) | 168,912 (50.0) | 168,912 (50.0) | |
| Asian | 225,590 (2.9) | 112,795 (50.0) | 112,795 (50.0) | |
| Hispanic | 218,912 (2.8) | 109,456 (50.0) | 109,456 (50.0) | |
| Otherd | 290,864 (3.7) | 145,432 (50.0) | 145,432 (50.0) | |
| Medicaid eligibility | 0 | |||
| No | 7,388,256 (93.7) | 3,694,128 (50.0) | 3,694,128 (50.0) | |
| Yes | 492,694 (6.3) | 246,347 (50.0) | 246,347 (50.0) | |
| No. of prior hospitalizations | 0 | |||
| 0 | 6,986,464 (88.6) | 3,493,232 (50.0) | 3,493,232 (50.0) | |
| 1 | 675,388 (8.6) | 337,694 (50.0) | 337,694 (50.0) | |
| ≥2 | 219,098 (2.8) | 109,549 (50.0) | 109,549 (50.0) | |
| Prior COVID-19 | 0 | |||
| No | 7,398,502 (93.9) | 3,699,251 (50.0) | 3,699,251 (50.0) | |
| Yes | 482,448 (6.1) | 241,224 (50.0) | 241,224 (50.0) | |
| Residence prior to original vaccination | 0 | |||
| Community | 7,754,612 (98.4) | 3,877,306 (50.0) | 3,877,306 (50.0) | |
| Nursing facility | 126,338 (1.6) | 63,169 (50.0) | 63,169 (50.0) | |
| Elixhauser comorbidity summary scoree | 0 | |||
| <0 | 2,126,332 (27.0) | 1,063,166 (50.0) | 1,063,166 (50.0) | |
| 0 | 3,235,364 (41.0) | 1,617,682 (50.0) | 1,617,682 (50.0) | |
| >0 | 2,519,254 (32.0) | 1,259,627 (50.0) | 1,259,627 (50.0) | |
| Comorbidity | ||||
| AIDS/HIV | 8855 (0.1) | 5291 (59.8) | 3564 (40.2) | 0.0131 |
| Alcohol abuse | 54,863 (0.7) | 26,185 (47.7) | 28,678 (52.2) | −0.0076 |
| Deficiency anemia | 828,691 (10.5) | 412,475 (49.8) | 416,216 (50.2) | −0.0031 |
| Autoimmune | 320,615 (4.1) | 172,836 (53.9) | 147,779 (46.1) | 0.0322 |
| Blood loss anemia | 61,522 (0.8) | 30,784 (50.0) | 30,738 (50.0) | 0.0001 |
| Leukemia | 50,294 (0.6) | 28,846 (57.4) | 21,448 (42.6) | 0.0326 |
| Lymphoma | 84,920 (1.1) | 48,371 (57.0) | 36,549 (43.0) | 0.0291 |
| Metastatic cancer | 86,287 (1.1) | 46,931 (54.4) | 39,356 (45.6) | 0.0185 |
| Solid tumor without metastasis, malignant | 643,506 (8.2) | 336,386 (52.3) | 307,120 (47.7) | 0.0271 |
| Solid tumor without metastasis, in situ | 65,541 (0.8) | 34,878 (53.2) | 30,663 (46.8) | 0.0118 |
| Cerebrovascular disease | 450,634 (5.7) | 218,597 (48.5) | 232,037 (51.5) | −0.0147 |
| Congestive heart failure | 542,345 (6.9) | 259,542 (47.9) | 282,803 (52.1) | −0.0233 |
| Coagulopathy | 182,966 (2.3) | 95,037 (51.9) | 87,929 (48.1) | 0.0120 |
| Dementia | 384,887 (4.9) | 164,584 (42.8) | 220,303 (57.2) | −0.0656 |
| Depression | 707,782 (9.0) | 340,174 (48.1) | 367,608 (51.9) | −0.0244 |
| Diabetes, complicated | 1,008,282 (12.8) | 488,161 (48.4) | 520,121 (51.6) | −0.0243 |
| Diabetes, uncomplicated | 666,844 (8.5) | 326,880 (49.0) | 339,964 (51.0) | −0.0119 |
| Drug abuse | 45,357 (0.6) | 21,245 (46.8) | 24,112 (53.2) | −0.0096 |
| Hypertension, complicated | 768,245 (9.8) | 377,091 (49.1) | 391,154 (50.9) | −0.0120 |
| Hypertension, uncomplicated | 3,602,908 (45.7) | 1,793,937 (49.8) | 1,808,971 (50.2) | −0.0077 |
| Liver disease, mild | 162,274 (2.1) | 83,002 (51.1) | 79,272 (48.8) | 0.0069 |
| Liver disease, moderate to severe | 22,436 (0.3) | 12,046 (53.7) | 10,390 (46.3) | 0.0079 |
| Chronic pulmonary disease | 859,326 (10.9) | 423,950 (49.3) | 435,376 (50.7) | −0.0093 |
| Neurologic disorders affecting movement | 207,529 (2.6) | 95,499 (46.0) | 109,030 (52.5) | −0.0167 |
| Seizures and epilepsy | 102,966 (1.3) | 48,370 (47.0) | 54,596 (53.0) | −0.0139 |
| Other neurologic disorders | 156,293 (2.0) | 73,808 (47.2) | 82,485 (52.8) | −0.0158 |
| Obesity | 844,919 (10.7) | 415,172 (49.1) | 429,747 (50.9) | −0.0120 |
| Paralysis | 88,903 (1.1) | 40,611 (45.7) | 48,292 (54.3) | −0.0185 |
| Peripheral vascular disease | 813,238 (10.3) | 400,660 (49.3) | 412,578 (50.7) | −0.0099 |
| Psychoses | 217,295 (2.8) | 105,050 (48.3) | 112,245 (51.7) | −0.0112 |
| Pulmonary circulation disease | 123,823 (1.6) | 61,804 (49.9) | 62,019 (50.1) | −0.0004 |
| Renal failure, moderate | 676,910 (8.6) | 333,376 (49.2) | 343,534 (50.8) | −0.0092 |
| Renal failure, severe | 148,570 (1.9) | 75,428 (50.8) | 73,142 (49.2) | 0.0043 |
| Hypothyroidism | 1,256,574 (15.9) | 631,890 (50.3%) | 624,684 (49.7) | 0.0050 |
| Other thyroid disorders | 224,160 (2.8) | 116,517 (52.0) | 107,643 (48.0) | 0.0135 |
| Peptic ulcer with bleeding | 40,476 (0.5) | 20,084 (49.6) | 20,392 (50.4) | −0.0011 |
| Valvular disease | 543,637 (6.9) | 276,922 (50.9) | 266,715 (49.1) | 0.0102 |
| Weight loss | 166,927 (2.1) | 80,917 (48.5) | 86,010 (51.5) | −0.0090 |
a
COVID-19, coronavirus disease 2019; max, maximum; min, minimum.
b
Data are presented as No. (percentage) of patients unless indicated otherwise. Percentages may not equal 100 because of rounding.
c
Values in parentheses in the first column are column percentages; values in the second, and third columns are row percentages.
d
Other race includes Pacific Islander, American Native, and all other races and ethnicities.
e
We applied weights to 38 Elixhauser conditions to calculate Elixhauser summary score.17